Business Wire

NY-IFF

10.2.2020 22:17:12 CET | Business Wire | Press release

Share
IFF Named to Barron’s 100 Most Sustainable Companies List for Third Consecutive Year

Regulatory News:

IFF (NYSE: IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent and nutrition, today announced its third consecutive recognition on Barron’s 100 Most Sustainable Companies List, an index first launched in February 2018. It joins the ranks of 99 other leading U.S. companies assessed for environmental, social and corporate governance practices.

“We are delighted to once again be named to Barron’s prestigious sustainability index,” said Andreas Fibig, IFF Chairman & CEO. “This recognition is further testament to our passionate employees across the world and IFF’s commitment to global sustainability leadership, as we redefine how we live in and care for the resources of our world.”

In partnership with U.S. based investment advisory firm Calvert Research and Management, the Barron’s list was compiled by evaluating the 1000 largest publicly traded companies against hundreds of ESG performance indicators. These indicators, which address topics such as workplace diversity, data security and greenhouse-gas emissions, were then used to rank each company’s performance in five key constituencies: shareholders, employees, customers, community and the planet.

IFF’s EVP, Chief Global Scientific & Sustainability Officer Dr. Gregory Yep said, “This is a fantastic achievement for IFF, where sustainability priorities remain deeply connected to the overall success of our organization. As IFF continues to grow and evolve, we remain focused on opportunities to create a smarter, greener and more viable company positioned to protect our planet and the well-being of future generations.”

Through 2019, the Company:

  • Continues to execute on its environmental goals focused on emission reductions, zero waste to landfill and water stewardship, known collectively as “EcoEffective+”
  • Signed the United Nations’ “Business Ambition for 1.5°C – Our Only Future” pledge, a campaign to put more aggressive science-based goals into action to help limit global temperature rise to 1.5 degrees Celsius
  • Received Double-A distinction from CDP, including recognition on CDP’s A List for Climate Change (fifth consecutive) and Water Security (second consecutive), reaffirming IFF’s global leadership in environmental responsibility
  • Opened the industry’s largest solar array at its Union Beach, New Jersey property, which is expected to generate over nine million kilowatt hours annually, powering IFF’s R&D facility and returning any excess energy to the grid
  • Deepened its commitment to diversity and inclusion by signing onto the United Nations Global LGBTI Standards of Conduct for Business (“the Standards”), joining 250 of the world’s largest companies in the pledge to tackle discrimination against lesbian, gay, bisexual, transsexual and intersex (LGBTI) people in the community, workplace and marketplace
  • Solidified its commitment to gender parity and women’s empowerment by pledging to adopt the United Nations Women’s Empowerment Principles (“the Principles”), a set of seven tenets to advance and empower women and provide equal treatment in the workplace, marketplace and community
  • Received the 2019 “Industry Mover” award from SAM, a subsidiary of RobecoSAM which specializes in providing ESG data, benchmarks and ratings, for the Company’s top-scoring performance in economic, social and environmental categories
  • Pledged to achieve a full global EDGE certification in 2020, to advance the Company’s certification from the Economic Dividends for Gender Equality (EDGE) for its business in the United States
  • Installed a series of nesting platforms to support the conservation of ospreys, a North American raptor species challenged by environmental changes

For more information on sustainability at IFF, visit https://www.iff.com/en/our-purpose/sustainability .

# # #

Welcome to IFF

At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com , Twitter , Facebook , Instagram , and LinkedIn .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yamaha to Acquire Disguise, Expanding Its Capabilities in Integrated Audio, Video, Lighting and Media13.11.2026 08:00:00 CET | Press release

Acquisition combines Yamaha’s audio expertise with Disguise’s software and media server technologies Yamaha Corporation today announced an agreement to acquire Disguise Technologies Limited (“Disguise”), a London-based provider of software and media server technologies for live and immersive experiences. Yamaha will acquire the company by purchasing all shares in its parent, Butterfly Topco Limited. The acquisition will expand Yamaha’s capabilities beyond audio into integrated audio, video, lighting and media solutions, in line with its strategy to expand beyond hardware into software and services. By combining Yamaha’s audio expertise and global reach with Disguise’s software, technologies and worldwide partner network, the companies will be better positioned to deliver immersive experiences across live entertainment, sports and other venues. Disguise’s technology powers live and immersive experiences worldwide, including tours by Beyoncé and Taylor Swift and venues such as New York’s

Mexico Becomes the First Market Worldwide to Receive Approval for Galderma’s Restylane® Shaype™ for Both Chin and Its First Jawline Indication13.11.2026 07:00:00 CET | Press release

Restylane Shaype is now approved in Mexico for temporary augmentation in the chin area and improvement of jawline definition,1 with launch anticipated in H1 2027 Already approved across various markets globally for the chin area,2 this marks Restylane Shaype’s first approval for the jawline worldwide1 The first-and-only shaper on the hyaluronic acid (HA) market, Restylane Shaype features the firmest HA gel available and is powered by proprietary NASHA HD™ technology, developed to build and shape on bone for instant, natural-looking contour and definition3-6 The approval reinforces Galderma's commitment to advancing innovation in the HA category, enabling the company to meet diverse patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that Restylane Shaype has been approved for temporary augmentation in the chin area and improvement of jawline definition in Mexico.1 This is the product’s first approval globally for the jawline, and further expan

vVARDIS Announces Pricing of Initial Public Offering13.11.2026 06:02:00 CET | Press release

vVARDIS Holding AG (“vVARDIS”), a Swiss healthcare company operating in the dental med-tech sector, today announced the pricing of its initial public offering of 9,722,223 Class A ordinary shares at a public offering price of $18.00 per share. In connection with the offering, vVARDIS has granted the underwriters a 30-day option to purchase up to an additional 1,458,333 Class A ordinary shares at the initial public offering price to cover over-allotments. The Class A ordinary shares are expected to begin trading on the New York Stock Exchange on November 13, 2026 under the symbol “VVVV.” The closing of the offering is expected to occur on or about November 16, 2026 subject to the satisfaction of customary closing conditions. Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint bookrunning managers for the offering, with William Blair, UBS Investment Bank and Deutsche Bank Securities acting as bookrunners. A registration statement on Form F-1 relating to the offering has been file

Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4*12.11.2026 23:07:00 CET | Press release

The multi-level takeover includes a Throne Room, interactive photo opportunities, special lighting, and more The Empire State Building (ESB) is the gateway to Mount Olympus in Percy Jackson’s world, and now fans can experience the magic like never before. On Nov. 16, the Empire State Building Observation Deck (ESBOD) will unveil “Olympus Awaits,” a multi-level “Percy Jackson and the Olympians” takeover, in partnership with Disney+. The immersive takeover – included with every Observation Deck ticket – will feature an epic Throne Room, interactive photo opportunities, surprise giveaways, ESB x “Percy Jackson” merch, and more, available through Dec. 4, 2026.* This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112442266/en/ Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4* “This immersive NYC experience

Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application12.11.2026 18:09:00 CET | Press release

Veristat’s InStat™ delivers submission-ready tables, listings, and figures (TLFs) in one week using validated statistical engines, shortening the critical path from database lock to submission VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that it has partnered with Clene Nanomedicine to cut the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%. Veristat reduced the time from study data to validated tables, listings and figures (TLFs) from up to six weeks to just one week. Clene, a late-stage biotech company, leveraged Veristat’s recently launched InStat™ platform, the industry’s first zero-code, fully automated solution to accelerate clinical trial processes. Biostatistical TLFs sit on the critical path for submissions, yet most sponsors rely on antiquated processes that involve slow, manual workflows to produce them, making post-database lock one of the biggest bottlenecks

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye